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Abstract Background: In Europe, Direct Healthcare Professional Communications
(DHPCs) are important tools to inform healthcare professionals of serious,
new drug safety issues. However, this tool has not always been successful in
effectively communicating the desired actions to healthcare professionals.
Objective: The aim of this study was to explore healthcare providers’ experi-
ences and their preferences for improvement of risk communication, comparing
views of general practitioners (GPs), internists, community pharmacists and
hospital pharmacists.
Methods: A questionnaire was developed and pilot tested to assess experi-
ences and preferences of Dutch healthcare professionals with DHPCs. The
questionnaire and two reminders were sent to a random sample of 3488 GPs,
internists and community and hospital pharmacists in the Netherlands.
Descriptive statistics were used to describe demographic characteristics of the
respondents. Chi squares, ANOVAs and the Wilcoxon signed rank test were
used, when appropriate, to compare healthcare professional groups.
Results: The overall response rate was 34% (N = 1141, ranging from 24% for
internists to 46% for community pharmacists). Healthcare providers trusted
safety information more when provided by the Dutch Medicines Evaluation
Board (MEB) than by the pharmaceutical industry. This was more the case
for GPs than for the other healthcare professionals. Respondents preferred
safety information to be issued by the MEB, the Dutch Pharmacovigilance
Center or their own professional associations. The preferred alternative chan-
nels of drug safety information were e-mail, medical journals and electronic
prescribing systems.
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Conclusions: Safety information of drugs does not always reach healthcare
professionals through DHPCs. To improve current risk communication of
drug safety issues, alternative and/or additional methods of risk commu-
nication should be developed using electronic methods and medical journals.
Moreover, (additional) risk communication coming from an independent
source such as the MEB should be considered. Special effort is needed to
reach GPs.
Introduction
At the time of market entry, the safety profile
of a drug is incomplete due to inherent and
known shortcomings of pre-marketing clinical
trials.[1] Recent studies have shown that 10–14%
of medicinal products require a Direct Health-
care Professional Communication (DHPC in the
EU; Dear Healthcare Professional letter in the
US) or ‘Dear Doctor’ letter (hereafter referred to
as a DHPC) to inform healthcare professionals of
newly identified risks within the first 3 years of
market approval.[2,3]
Effective risk communication is essential to pre-
vent or minimize harm. Evaluation of commu-
nication about cisapride and selective serotonin
re-uptake inhibitors (SSRI) has shown that it is
not always possible to achieve desired actions by
healthcare professionals through risk commu-
nication. After safety warnings were issued an-
nouncing that the use of certain medications in
combination with cisapride could cause severe
cardiovascular problems, prescribing of cisapride
with contraindicated medication continued, lead-
ing to its market withdrawal.[4,5] Although the
SSRI warnings were only aimed at reducing new
prescriptions in adolescents, unintended decreases
in SSRI prescribing in adults were also observed.[6-8]
Currently, the paper-based DHPC is a major
tool in risk communication of drug safety issues.
In the EU, DHPCs are sent to pre-specified target
groups of healthcare professionals by the pharma-
ceutical industry as commissioned by the European
Medicines Agency and national authorities.[9]
Since effectiveness of risk communication de-
pends largely on trust in the source of the in-
formation,[10] it is important to evaluate how
different sources are perceived by healthcare pro-
fessionals. In addition, evaluation of the effec-
tiveness of risk minimization measures will become
mandatory in the EU with the new pharma-
covigilance legislation that came into force in
July 2012.[11,12]
Tooptimize current risk communicationmethods
and to improve implementation of any necessary
actions into clinical practice, it is important to
have good insight into the preferences of health-
care professionals. A tailor-made approach that
incorporates preferences of different healthcare
professional groups may facilitate the uptake of
the risk information as well as implementation of
the desired actions.[13] To date, little information
is available on preferences of different healthcare
professional groups. The aim of this study was to
explore healthcare providers’ experiences and their
preferences for risk communication of safety issues
of medicines, comparing the views of GPs, inter-
nists and community and hospital pharmacists.
Methods
Questionnaire Development
An explorative literature search did not result
in any validated questionnaires that could be used
in our study. Hence, a questionnaire with open-
ended and closed questions was developed using
the ‘knowledge, attitudes, behaviour’ framework
introduced by Cabana et al.[14]
The attitude of healthcare professionals towards
risk information was assessed with a number of
statements (table I). All attitude-related statements
were rated on a 5-point Likert scale ranging from
(1) strongly disagree to (5) strongly agree.
The healthcare professionals were then asked
various knowledge-related questions, and were
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Table I. Questionnaire overviewa
Section/question Answer categories
Attitude
1. I think information about drug safety is important 1: Strongly disagree – 5: strongly agree
2. It takes too much time to remain up to date on new drug safety issues 1: Strongly disagree – 5: strongly agree
3. I think the MEB is knowledgeable about drugs 1: Strongly disagree – 5: strongly agree
4. I think information from the MEB is trustworthy 1: Strongly disagree – 5: strongly agree
5. I think the pharmaceutical industry is knowledgeable about drugs 1: Strongly disagree – 5: strongly agree
6. I think information from the pharmaceutical industry is trustworthy 1: Strongly disagree – 5: strongly agree
Knowledge
7. Have you ever seen a DHPC? Yes
No, I have heard of DHPCs, but I have never seen one
No, I have never heard of DHPCs
8. Do you read the DHPCs you receive? No, I do not read any letters from the pharmaceutical industry,
either in an orange hand envelopeb or not
Yes, if they contain safety information that is important to me
Yes, only if they are sent in an orange hand envelope
Yes, only when the envelope indicates it contains important,
non-commercial information
Yes, I read all letters from the pharmaceutical industry
9. Do you visit the MEB website for specific information on drug safety issues? Never, I never heard of the MEB
Never, I did not know the MEB had a website
Never, I did know the MEB has a website





10. Are you aware of the safety issues of the following drugs for which




11. If yes; how did you receive this information (DHPC; Website MEB; Media;
Specialist journal; electronic mailing/internet; other, namely)?
Yes
No – Several answers possible
Behaviour
12. Can you estimate in which percentage of the received DHPCs you
undertook action (e.g. adjusting therapy, inform colleagues, discuss
with patient)?
Visual analogue scale ranging from 0% to 100%
Preferences for alternative methods
13. What do you think of the current method (DHPC) with which you are
informed of new drug safety issues?
1: Very poor – 10: very good
14. How useful do you consider repetition is of the safety information
(e.g. repetition of the letter or e-mail)?
1: Not at all useful – 10: very useful
15. How useful do you consider receiving safety information is through several
methods at the same time (e.g. both postal and by e-mail)?
1: Not at all useful – 10: very useful
16. Which of the following information channels do you think are suitable for
fast information about new drug safety issues (e-mail; text message; twitter;
electronic newsletter; medical journals; RSS feed; computerized prescription
system)?
1: Not all useful – 10: very useful.
Separately rated for each channel
17. Which of the following senders do you think are suitable for fast
information about new drug safety issues (physician/pharmacist;
professional association; Lareb; pharmacotherapy meetings; media;
drug compendium)?
1: Not at all useful – 10: very useful.
Separately rated for each sender
Continued next page
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presented with four specific drugs with safety is-
sues (rimonabant and depression, moxifloxacin
and skin reactions and hepatoxicity, clopidogrel
and interaction with proton pump inhibitors,
etoricoxib and hypertension).[15] These four
drugs were chosen because DHPCs regarding
these issues were sent to all groups of healthcare
professionals included in this study within the
23 months preceding the first questionnaire.
The respondents were asked if they were aware
of these safety issues and, if so, what their source
of information was (DHPC, Dutch Medicines
Evaluation Board [MEB] website, lay media,
medical journal, electronic mailing/internet and/
or other).
With regard to the behaviour component of
the questionnaire, respondents were asked in what
percentage of DHPCs was action taken. Respon-
dents rated this question using a visual analogue
scale ranging from 0% to 100%.
Preferences for improved risk communication
were assessed on a 10-point Likert scale ranging
either from (1) very poor to (10) very good or
from (1) not at all useful to (10) very useful. The
respondents’ preferences for alternative channels
(e-mail, text message, twitter, electronic news-
letters, medical journals, RSS1 feeds and compu-
terized prescription system) and sources (physician/
pharmacist, professional association, Netherlands
Pharmacovigilance Centre, MEB, pharmaco-
therapy meetings, media, drug compendium)
of risk communication were explored using a
10-point Likert scale ranging from (1) not at all
useful to (10) very useful. The most appropriate
answering scale was chosen for each individual
question.
The following demographic aspects were col-
lected: specific profession, sex, period of regis-
tration as a healthcare professional, full-time or
part-time employment.
Face validity of the questionnaire was eval-
uated by five professionals (two physicians, two
pharmacists, one regulator), after which changes
were made to the layout, wording and pre-
defined answers. The questionnaire was then sent
to a random sample of 50 healthcare profes-
sionals to test its feasibility. Further changes were
made to improve the clarity of the questionnaire.
The pilot test data were not included in the final
data analysis.
Study Population
Healthcare professionals living in theNetherlands
were surveyed. GPs and internists (doctors of in-
ternal medicine) were included since they pre-
scribe a wide range of drugs and therefore have
a high likelihood of dealing with risk commu-
nications of drug safety issues. Hospital and
community pharmacists were included because
of their central role in drug dispensing and in-
formation. Respondents were excluded if they
were no longer actively working as a physician or
pharmacist (n = 11).
Addresses of the healthcare professionals were
obtained from the Dutch Internist Association
Table I. Contd
Section/question Answer categories
18. Are you willing to provide the MEB with your e-mail address and/or mobile
phone number to receive specific information about drug safety issues?
Yes, but only my e-mail address
Yes, but only my mobile phone number
Yes, both my e-mail address and my mobile phone number
No
a Eighteen of the 25 questions posed in the survey are represented. Seven questions are not included here as they did not provide directly
relevant information or they produced responses that demonstrated the so-called ‘halo effect’.
b Orange hand envelope: safety issues requiring immediate action (e.g. in case of contaminated batches of drugs) are sent in envelopes with
an orange hand printed on them, to attract the attention of the healthcare professional.
DHPC =Direct Healthcare Professional Communication; Lareb =Netherlands Pharmacovigilance Center; MEB=Dutch Medicines Evaluation
Board; RSS =Really Simple Syndication.
1 RSS (Really Simple Syndication) feeds make it possible to see when websites have added new information,
such as, for example, news headlines and press releases. RSS feeds make checking separate websites unnecessary.
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(NIV) and the Dutch Pharmacist Association
(KNMP). Most (~90%) of the Dutch internists
and pharmacists are members of their profes-
sional association, partly because accreditation
of training is arranged within these associations.
The Netherlands Institute for Health Services
Research (NIVEL) provided a random sample of
Dutch GPs. A sample size calculator[16] was used
to determine the number of respondents that
would be needed to obtain the appropriate sam-
ple size to result in 80% power to detect a 10%
difference in healthcare providers’ ratings of in-
dividual questions.
We adjusted the sample size based on the res-
ponse rates observed in the feasibility study,
where response ranged from 20% to 80% for in-
ternists and community pharmacists, respectively
(see table II). This resulted in sending ques-
tionnaires to 3488 healthcare professionals (700
randomly selected GPs, 700 randomly selected
community pharmacists, all 1696 Dutch internists
and all 392 hospital pharmacists) in the Nether-
lands in December 2009.
The anonymous questionnaire was sent with
a cover letter and a prepaid return envelope. To
maximize the response, a total of two reminders
accompanied by the questionnaire were sent at
month 1 and 2 after the initial mailing.[17]
Data Entry and Analysis
Data were entered by three data entry assis-
tants using structured data entry forms. Data
entry was checked by examining duplicate entries
of 10% of all returned questionnaires for errors.
The duplicate data entry resulted in less than
0.1% error in the entered variables. The majority
of the data entry errors (83%) were related to
questions 10 and 11 (table I). All entries of these
two questions were therefore compared with the
original returned questionnaires and corrected
when appropriate.
Assuming that the respondents who returned
the questionnaire only after a reminder were most
comparable to non-responders, sensitivity analyses
were performed to explore possible differences
between initial and late responders, on the main
questions of trust, knowledge and preferences.
Descriptive statistics were used to describe demo-
graphic characteristics of the respondents. Chi
squares, ANOVAs and the Wilcoxon signed rank
test were used when appropriate to compare














Totala 1,141 (34) 233 (33) 410 (24) 323 (46) 175 (45)
Initial mailing 686 (60) 112 (48) 269 (66) 184 (57) 121 (69)
Reminder 1 358 (31) 67 (27) 137 (33) 101 (31) 53 (30)
Reminder 2 97 (9) 54 (23) 4 (1) 38 (12) 1 (1)
Pilot (N =50) 22 (44) 6 (40) 3 (20) 8 (80) 5 (50)
Healthcare professional characteristics
Female (4 missing) 465 (40) 97 (42) 141 (34) 146 (45) 81 (47)
Years of professional accreditation (2 missing)
Trainee 7 (1) 1 (0) 0 (0) 5 (2) 1 (1)
1–5 207 (18) 24 (10) 87 (21) 58 (18) 38 (22)
6–10 240 (21) 47 (20) 76 (19) 68 (21) 49 (28)
11–15 173 (15) 37 (16) 49 (12) 61 (19) 26 (15)
‡16 512 (45) 124 (53) 197 (48) 130 (40) 61 (35)
Working part time (3 missing) 258 (22) 78 (34) 57 (14) 72 (22) 51 (29)
a Differences in percentages may exist due to rounding.
GP =General Practitioner.
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healthcare professional groups. Datawere analysed
using SPSS 16.0 software (SPSS, Inc., Chicago,
Illinois, USA).
Results
The questionnaire and reminders were sent to
3488 healthcare professionals in the Netherlands
in December 2009 and January 2010, resulting in
an overall response rate of 34% (N = 1141; rang-
ing from 24% for internists to 46% for com-
munity pharmacists) [table II]. Most healthcare
professionals who returned our questionnaire
were male (60%), working full-time (78%) and re-
gistered as a healthcare professional for 15 years
or fewer (55%).
Attitude
The majority (mean – SD) of the healthcare
professionals considered risk information of medi-
cinal products to be important (4.67– 0.6), ranging
from an average of 4.55– 0.5 reported by theGPs to
4.77– 0.5 by the hospital pharmacists (p£ 0.0001).
Most healthcare professionals did not have an
opinion, or had a neutral attitude about the
statement ‘It takes too much time to remain up to
date on new drug safety issues’ (2.56 – 0.9). The
GPs (2.80 – 1.0) more often reported that re-
maining up to date took too much time, while the
community pharmacists indicated this the least
often (2.39 – 0.9; p£ 0.001).
The healthcare professionals considered both
the MEB and the pharmaceutical industry knowl-
edgeable about drugs (4.06 – 0.7 and 3.91 – 0.7,
respectively), but trusted the risk information
provided by the MEB more (4.13 – 0.6 and 2.70 –
0.8, respectively; p£ 0.001; figure 1). In particular,
the GPs thought that information provided by
theMEBwas significantly more trustworthy than
information provided by the pharmaceutical in-
dustry (p £ 0.001).
Knowledge
Sixteen percent of the healthcare professionals
(ranging from 5% of the hospital pharmacists to
28% of the GPs; p£ 0.001) were not familiar with
DHPCs. The majority (58%) of the healthcare
professionals indicated that they read only the
DHPCs that contained information that was
relevant to them, and 30% of the community
pharmacists read all letters they received from the
pharmaceutical industry (p £ 0.001).
Four specific drugs with safety issues were pre-







































Fig. 1. Trust and knowledge attributed to the Dutch Medicines Evaluation Board/pharmaceutical industry.
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bant, moxifloxacin, clopidogrel and etoricoxib).
Most healthcare professionals indicated that they
were aware of all four safety issues, ranging from
56% for the etoricoxib issue to 88% for the clo-
pidogrel issue (figure 2). The pharmacists were
better informed than the physicians (p £ 0.001)
for all safety issues except etoricoxib. In the
etoricoxib case, primary care healthcare profes-
sionals (GPs and community pharmacists) were
more aware of the safety issue (67% and 71%,
respectively) than the secondary care healthcare
providers (internists and hospital pharmacists;
40% and 51%, respectively; p £ 0.001). Know-
ledge of the four safety issues was mostly ob-
tained from professional journals (59%) and
DHPCs (49%), while the MEB website was rarely
indicated (5%) as the information source.
Sixty-four percent of the respondents indi-
cated that they never visited the MEB website to
search for more information about safety issues.
Seven percent of the healthcare professionals
were not aware of the existence of theMEB. Only
6% of the respondents visited the website weekly
and only 1% did so daily. Hospital and com-
munity pharmacists were more aware of theMEB
and visited the MEB website more often than
internists and GPs (p £ 0.001), although 38% of
the pharmacists visited the website only monthly
or 6 monthly.
Behaviour
The healthcare professionals reported to have
taken action (e.g. adjusting therapy, informing
colleagues, discussion with patient) in response to
29% of the DHPCs, ranging from 23% of internists
to 37% of community pharmacists (p£ 0.001).
Preferences for Improved Risk
Communication
Satisfaction with the current way of risk com-
munication was rated as mean 6.9 (SD –1.9) out
of 10, ranging from 6.0 – 2.1 on average byGPs to
7.6– 1.4 by community pharmacists (p£ 0.001).
Repetition of the risk communication as well as
information coming from several sources si-
multaneously was rated as moderately useful






























GP HP CP INT GP HP CP INT GP HP CP INT GP
Fig. 2. Healthcare providers’ knowledge of safety issues of four drugs. CP = community pharmacist; GP =general practitioner; HP = hospital
pharmacist; INT = internist; PPI = proton pump inhibitor.
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ended question regarding which specific combi-
nation was preferred yielded responses from 494
healthcare professionals (multiple answers were
given). Predominantly, a combination of the paper-
based DHPC with an e-mail was suggested
(n = 184). Receiving risk information via e-mail
only was indicated 91 times and via the paper-
based DHPC only was indicated 41 times.
The preferred alternative channels of risk in-
formation were e-mail, medical journals and
electronic prescribing systems. The preferences
for these three channels varied across the four
healthcare professional groups (table III). RSS
feeds, text messages and twitter were not favoured
methods. According to the healthcare profes-
sionals, risk communication should preferably be
issued by the MEB, the Dutch Pharmacovigilance
Center (Lareb) or their own professional associa-
tion (table III). The media were rated as the least
preferable source of risk communication.
Sensitivity analyses showed significant differ-
ences between responders to the initial mailing
and the two subsequent reminders in only two
preference variables. In those two cases, the late
responding physicians rated safety information
coming from pharmacists higher than did physi-
cians responding to the initial mailing (p = 0.007).
The late responding healthcare professionals also
rated the pharmacotherapy meetings higher than
did early responding healthcare professionals
(p £ 0.001).
Discussion
Although the responding healthcare profes-
sionals considered risk information on drug
safety issues to be important, a substantial group
was not familiar with the DHPC as a tool for risk
information. Pharmacists appeared to be more
aware of, and more responsive to, safety issues
than physicians, particularly GPs. The majority
of the healthcare professionals preferred to receive
drug safety information from an independent
source such as theMEB or their own professional







E-mail 7.16 (2.5) 7.24 (2.5) 8.07 (1.8) 8.09 (2.0) 7.59 (2.3) £0.001b
Text message 232 (1.9) 2.13 (1.7) 3.05 (2.4) 2.41 (2.3) 2.47 (2.1) £0.001b
Twitter 1.72 (1.2) 1.65 (1.2) 2.13 (1.8) 1.68 (1.4) 1.81 (1.4) £0.001b
Electronic newsletter 5.66 (2.9) 5.99 (2.8) 6.53 (2.4) 6.37 (2.8) 6.14 (2.7) £0.001b
Medical journals 7.32 (2.2) 7.85 (1.7) 7.32 (2.0) 7.15 (2.2) 7.49 (2.0) £0.001b
RSS feeds 3.44 (2.4) 3.74 (2.7) 4.05 (2.7) 5.06 (3.0) 3.98 (2.8) £0.001b
Computerized prescription system 7.83 (2.2) 6.52 (3.1) 7.45 (2.4) 7.03 (2.6) 7.14 (2.7) £0.001b
Source
Physician (by pharmacists) NA NA 4.76 (2.5) 3.90 (2.4) 4.46 (2.5) £0.001b
Pharmacist (by physicians) 8.14 (1.8) 6.90 (2.4) NA NA 7.35 (2.3) £0.001b
Professional association 7.60 (1.9) 7.98 (1.7) 8.27 (1.4) 7.93 (1.9) 7.98 (1.7) £0.001b
Lareb 7.82 (1.8) 7.98 (1.8) 8.37 (1.2) 8.00 (1.8) 8.06 (1.7) £0.001b
MEB 7.70 (1.8) 7.94 (1.6) 8.38 (1.2) 8.64 (1.2) 8.13 (1.5) £0.001b
Pharmacotherapy meetings 7.63 (2.1) 4.94 (2.3) 6.06 (2.4) 4.55 (2.3) 5.76 (2.5) £0.001b
Media 3.90 (2.2) 3.90 (2.3) 3.78 (2.3) 3.42 (2.2) 3.79 (2.2) =0.101
Drug compendium 7.41 (2.1) 7.19 (22) 6.29 (2.6) 5.40 (2.8) 6.71 (2.5) £0.001b
a All channels and sources were rated on a 10-point Likert scale ranging from (1) not at all useful to (10) very useful.
b Indicates significant (p £ 0.05) differences in preference between the four healthcare provider groups in the ANOVA analysis.
GP =general practitioner; Lareb =Dutch Pharmacovigilance Centre; MEB=Dutch Medicines Evaluation Board; NA= not applicable;
RSS =Really Simple Syndication.
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association than from DHPCs. Moreover, most
healthcare professionals preferred to receive the
information through medical journals or elec-
tronically, for example, by e-mail or electronic
(prescribing) systems.
Fifteen percent of the respondents had never
heard of or seen aDHPC. This percentage is simi-
lar to the results from an earlier study performed
in the US, where 18% of the respondents indicated
they had never seen a DHPC.[18] In contrast, other
studies reported higher percentages of respondents
with knowledge of drug safety warnings.[19-21]
Awareness of the specific safety issues and re-
ported action in response to a DHPC was higher
among pharmacists. In addition, they visited the
MEB website more frequently than physicians.
This might be explained by the focus of pharma-
cists on pharmacotherapy and drug risks, while
for physicians this aspect might have a lower
priority. This is supported by the finding that the
physicians rated ‘keeping up to date on risk in-
formation’ as time consuming more often than
pharmacists.
Awareness of the four safety cases ranged
from moderate for the etoricoxib issue (55%) to
high for the clopidogrel issue (85%). Pharmacists
were better informed than physicians, except
in the etoricoxib case, where the GPs and com-
munity pharmacists were more aware of the
safety issue than hospital pharmacists and inter-
nists. Etoricoxib is mainly prescribed and dis-
pensed in primary care, which could explain this
finding. Only in the moxifloxacin case was the
DHPC indicated as the main risk information
source. In the other three cases, the information
was mainly obtained from professional journals.
This is in line with earlier research, which found
that healthcare professionals mainly use sources
of safety information other than the DHPC.[22,23]
The respondents reported having taken action
in relation to 29% of the DHPCs they received.
This percentage is higher than that reported by
Canadian healthcare professionals, which ranged
from 2% adjusting their prescribing to 16% for-
warding the DHPC to other healthcare profes-
sionals.[19] In other studies, higher percentages of
action were reported by healthcare professionals,
e.g. changes in prescribing behaviour of 80% re-
lated to an antidepressants black-box warning,[20]
and 40% related to a long-acting beta agonists
black-box warning.[21] It should be noted that not
all DHPCs require immediate action from all
healthcare professionals.
The preference for receiving drug safety in-
formation from an independent organization is in
line with findings of earlier studies. Physicians in
the UK and the US prefer independent sources
(e.g. medical journals and colleagues) over com-
mercial (e.g. pharmaceutical companies) and
third-party sources (e.g. general media).[22,23] The
respondents in our study, especially the GPs, in-
dicated they would have more trust in drug safety
information coming from theMEB than from the
pharmaceutical industry. Trust in both the sender
and the information itself plays an essential role
in successful risk communication.[24] It is suggested
that inadequate risk communicationmay be caused
by insufficient trust in the institutions that are
responsible for risk management.[10]
E-mail and electronic prescribing/dispensing
systems, the preferred channels of respondents,
could prove to be good channels of risk commu-
nication because of their user-friendliness. Such
an e-mail would preferably consist of a short
summary of the drug safety issue and the recom-
mendations to the healthcare professional on how
to manage the safety issue. A link to the DHPC
and to background information on the drug
safety issue could be incorporated in the e-mail.
The header of the e-mail should clearly indicate
the safety issue and the drug in question. Pre-
sently, the MEB already offers an e-mail service
to voluntary subscribers. In our survey, 84% of
the respondents indicated they were willing to
provide the MEB with their e-mail address to
receive such an e-mail. The physicians, especially
the GPs, rated pharmacists quite highly as an al-
ternative source of safety information. Informa-
tion from professional associations was also a
preferred alternative. A more active involvement
of these groups as intermediaries in the risk com-
munication process could be an important addi-
tional step to strengthen this process.
One of the aims of DHPCs is to rapidly inform
healthcare professionals when a safety issue is
identified. However, it should be noted that
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incorporating warnings of safety issues into elec-
tronic prescribing/dispensing systems requires some
time, which could cause unnecessary harm to
patients. E-mail could prove to be more useful in
rapidly informing healthcare professionals, and
incorporating warnings in electronic prescribing/
dispensing systems may additionally be applied.
The respondents indicated they would not prefer
to receive safety information through methods
such as twitter, RSS feeds and text messaging,
even though communication through these me-
thods could be implemented relatively easily.
Since these are relatively novel methods, it may
be worthwhile to keep track of how the use of and
preference for these methods develop.
A substantial number of respondents indi-
cated that they would prefer to receive the safety
information via both the paper-based DHPC and
an additional e-mail. However, repetition of the
risk information as well as receiving information
simultaneously from several sources was rated as
only moderately useful. This apparent discrep-
ancy indicates that a fine balance seems to exist
between a preference for receiving the informa-
tion through various methods and an overload of
information. This is important to note, since such
an overload could easily cause ‘warning fatigue’,
resulting in healthcare professionals not taking
notice of risk communications.
The limited awareness that healthcare profes-
sionals had of the MEB and the MEB website
seems to be comparable to familiarity with other
national authorities. In the UK for example, ap-
proximately 20% of the healthcare professionals
indicated they were aware of the Medicines and
Healthcare products Regulatory Agency
(MHRA).[23] In Canada, 38% of the healthcare
professionals were familiar with the drug safety
advisories on the Health Canada website, but
only 9% of the healthcare professionals visited
this website to retrieve new drug safety informa-
tion.[19] A focus group study performed in Canada
indicated that the ‘reporting authority is per-
ceived as a virtual and remote entity’.[25] Al-
though it appears that healthcare professionals
see a clear role for regulating authorities in com-
municating safety issues, their visibility amongst
healthcare professionals should be improved.
Strengths and Limitations
This is one of the first studies assessing
healthcare professionals’ opinions of DHPCs. A
sizable group of 1141 healthcare providers, both
pharmacists and physicians, were included in our
survey. We used a pre-tested questionnaire, pre-
serving the anonymity of the respondents to re-
duce the possibility of socially desirable answers.
Limitations to this study include a fairly low
response rate, with only 34% of the healthcare
providers responding. This is comparable to
other surveys amongst healthcare professionals,
especially amongst physicians.[20,21,26] Still, the
low response may have biased our results in
that healthcare professionals who are unaware
of, or not interested in, DHPCs could be under-
represented in our sample. This might mean that,
in reality, even fewer healthcare professionals are
aware of DHPCs and safety issues, which un-
derlines the need for improvements in current risk
communication. We were unable to analyse any
characteristics of the non-responders due to the
anonymous nature of the questionnaire. We can
only report that our sample is representative for
the Dutch setting in terms of sex,[27] and the
percentage of GPs who work part-time.[28] We
found no significant differences between early
and late responders, except for two preference
variables. It is possible that the non-responders
have different preferences with regard to the
pharmacists and pharmacotherapymeetings than
the responders. We can conclude that, apart from
these two variables, our results are, in all like-
lihood, not affected by non-response bias. Due to
the anonymous nature of the questionnaire, it is
possible that healthcare professionals might have
responded to both the initial mailing as well as
the reminders. However, in the cover letters of the
reminders, we explicitly stated that these mailings
concerned reminders, which should be ignored if
the questionnaire had already been returned.
Since the reminders were sent within a month of
the previous mailing, and because of the specific
topic, we assume that the respondents would
have remembered filling out the earlier ques-
tionnaire. This was underlined by the fact that
some respondents actually notified us about this.
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It should be noted that ‘action in response to
DHPCs’ was a self-reported measure. Respondents
may have had difficulties remembering the num-
ber of DHPCs they received for which they
actually took action, leading to possible recall
bias. We cannot rule out that some healthcare
professionals may perceive a DHPC as informa-
tion from the pharmaceutical industry, despite
our explanation in the questionnaire that a DHPC
is issued on request from and in collaboration with
the MEB. This might have influenced their re-
sponses to several questions, for example questions
8 (reading the DHPCs) and 13 (satisfaction with
the current communication method).
Conclusions
Healthcare professionals consider staying up
to date on new drug safety issues important, al-
though a fair proportion were not aware of the
DHPC as a risk communication tool. Those that
were aware rated this risk communication method
as reasonable, but valued electronic methods
as alternative or additional risk communication
channels. In line with this, healthcare profes-
sionals indicated mainly other channels as the
source for their knowledge of some recent drug
safety issues. Our study also showed that health-
care professionals had greater trust in the MEB
than in industry as a source of drug safety in-
formation and that they would prefer to be in-
formed through independent organizations.
Therefore, current risk communication of
medicinal products should be improved, preferably
by using electronic methods, including e-mail and
electronic prescription systems, and/or medical
journals. Moreover, (additional) safety informa-
tion should come from an independent source
such as the MEB to optimize credibility. The re-
sults of this study indicate that additional efforts
are needed to ensure that the safety information
reaches healthcare professionals.
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